VivoSeq
Respiratory

Respiratory Failure

58

Pipeline Programs↗

11

Active Trials↗

28

Companies Involved↗

Respiratory Failure is a moderately active landscape with 58 programs across 28 companies. The most active players are Cynata Therapeutics Limited, Bayer, Asklepion Pharmaceuticals, LLC. 20 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

15/100

Mech. Concentration

8/100

Completion Rate

61/100

Attrition Rate

30/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cynata Therapeutics Limited

1 program

Phase 1Bayer logo

Bayer

2 programs

Phase 2A

Asklepion Pharmaceuticals, LLC

1 program

Phase 2H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 2Roche logo

Roche

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical4

Methylprednisolone

Pfizer

Cisatracurium

AbbVie

Decidual Stromal Cells

Karolinska Institutet

Proteocit

University Hospital, Grenoble

Phase 13

Human Amniotic Fluid

University of Utah

RLS-0071

ReAlta Life Sciences, Inc.

CYP-001

Cynata Therapeutics Limited

Phase 221

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Tocilizumab

Roche

Thiamine

Universiti Kebangsaan Malaysia Medical Centre

L-Citrulline

Asklepion Pharmaceuticals, LLC

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 310

Dapagliflozin

AstraZeneca

Resatorvid

Takeda

Inhaled Nitric Oxide

Lee's Pharmaceutical Limited

NK-1R Antagonist

Prof. Dr. Fridoon Jawad Ahmad

Standard Practice

NICHD Neonatal Research Network

Approved20

Hydroxychloroquine

Alnylam Pharmaceuticals

Fentanyl

Cephalon

Nitric Oxide

Mallinckrodt

Ketamine

Aultman Health Foundation

Propofol

Fresenius Kabi Oncology Ltd.

Analysis

Modality Breakdown

92%

Small molecule

58 of 63 classified programs — the dominant modality here.

8%ALL OTHERSProtein / enzyme35%Monoclonal antibody12%Cell therapy12%

Small molecule leads; the ring shows all 63 classified programs, each share of the total. Modality classified for 100% of 67 pipeline programs.

Analysis

Trial Status

64

clinical trials

Completed30 · 47%
Terminated15 · 23%
Recruiting10 · 16%
Withdrawn4 · 6%
Unknown status4 · 6%
Not yet recruiting1 · 2%

Clinical Trials

Trial Activity

64 trials

Partial Neuromuscular Blockade in Acute Hypoxemic Respiratory Failure
Recruiting·UUniversity Health Network, Toronto·N/A·NCT04524585·23 enrolled
Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma
Recruiting·UUniversity Hospital, Strasbourg, France·Phase 3·NCT03368092·500 enrolled
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
Recruiting·UUniversity of Alabama at Birmingham·Phase 3·NCT05026749·370 enrolled
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
Recruiting·MM.D. Anderson Cancer Center·N/A·NCT02464696·256 enrolled
Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions
Recruiting·—·Phase 4·NCT04545242·980 enrolled
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Recruiting·—·Phase 2·NCT04445285·44 enrolled
Improving Chronic Nocturnal Noninvasive Ventilation: a Multimodality Approach
Recruiting·UUniversity Medical Center Groningen·N/A·NCT05756387·100 enrolled
Assessment of Reintubation Risk Using Multiple Parameters in Postoperative Intensive Care Unit Patients
Recruiting·Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization·N/A·NCT07672106·600 enrolled
Evaluation of the Effects of the Oxygen Supplementation During 6-minute Walking Test in Patients With Chronic Respiratory Failure or Exertional Hypoxiemia
Recruiting·IIstituti Clinici Scientifici Maugeri SpA·Preclinical·NCT07451977·114 enrolled
Improving Psychological Outcomes for Acute Respiratory Failure Survivors Using a Self-Management Intervention
Recruiting·JJohns Hopkins University·Preclinical·NCT06341972·60 enrolled
Chinese Adaptive Randomised Pneumonia Trial With Respiratory Failure
Not yet recruiting·PPeking Union Medical College Hospital·Phase 4·NCT07396701·1,500 enrolled
Dapagliflozin in Respiratory Failure in Patients With COVID-19
Completed·SSaint Luke's Health System·Phase 3·NCT04350593·1,250 enrolled
Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure
Completed·UUniversity Hospital, Ghent·Phase 2·NCT04382755·81 enrolled
IRAD2 : Patients With Respiratory Failure at Home
Completed·UUniversity Hospital, Grenoble·Phase 3·NCT00230984·200 enrolled
Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure
Completed·—·Phase 2·NCT04420741·80 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)